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Abstract 
Background Height and body mass index (BMI) are associated with higher ovarian cancer risk 
in the general population, but whether such associations exist among BRCA1/2 mutation carriers 
is unknown. 
Methods We applied a Mendelian randomization approach to examine height/BMI with ovarian 
cancer risk using the Consortium of Investigators for the Modifiers of BRCA1/2 (CIMBA) 
dataset, comprising 14,676 BRCA1 and 7,912 BRCA2 mutation carriers, with 2,923 ovarian 
cancer cases. We created a height genetic-score (height-GS) using 586 height-associated variants 
and a BMI genetic-score (BMI-GS) using 93 BMI-associated variants. Associations were 
assessed using weighted Cox models.  
Results Observed height had no significant association with ovarian cancer risk (hazard ratio 
[HR]: 1.07 per 10-cm increase in height, 95% confidence interval [CI]: 0.94–1.23). Height-GS 
showed similar results (HR=1.02, 95%CI: 0.85–1.23). Higher BMI appeared to increase risk in 
premenopausal women significantly with HR=1.25 (95%CI: 1.06–1.48) and HR=1.59 (95%CI: 
1.08–2.33) per 5-kg/m2 increase in observed and genetically determined BMI, respectively. No 
association was found for postmenopausal women. Interaction between menopausal status and 
BMI was significant (Pinteraction<0.05).  
Conclusion Our observation of a positive association between BMI and ovarian cancer risk in 
premenopausal BRCA1/2 mutation carriers was consistent with findings in the general population.  
 
Keywords: ovarian neoplasms, Mendelian randomization, BRCA1, BRCA2, body height, body 
mass index 
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Introduction 
Ovarian cancer is the fifth leading cause of cancer deaths in US women, due to its 
typically advanced stage at presentation.
1,2
 Furthermore, unlike breast or colorectal cancer, there 
is no proven screening method for ovarian cancer to identify early disease and initiate treatment 
to improve survival.
3,4
 Family history,  oral contraceptive use, parity, body mass index (BMI), 
and genetic variants are potentially useful in estimating lifetime risk.
1
 In particular, inherited 
BRCA1 and BRCA2 mutations are associated with increased lifetime risk of ovarian cancer and 
account for ~10-15% of overall disease incidence.
5-7
 However, among mutation carriers, age at 
diagnosis is variable. Penetrance of BRCA1/2 mutations is likely modified by other genetic 
variants and lifestyle/reproductive factors.
8,9
 Investigation of these factors could aid in 
implementation of strategies to reduce ovarian cancer risk among mutation carriers.  
Both height and BMI are quantitative traits with substantial genetic bases. In recent 
genome-wide association studies (GWAS), numerous genetic variants were found to be 
associated with these traits.
10,11
 In the general population, both height and BMI appear to be 
positively but inconsistently associated with risk of ovarian cancer.
12-14
 Previous studies also 
showed that the association between BMI and ovarian cancer was stronger in premenopausal 
women.
12,15,16
 Because of differences in age at onset and tumor histology/grade, risk factors for 
ovarian cancer might be different for BRCA1/2 mutation carriers and general populations.
17
 Only 
one case-control study, with 469 ovarian cancer cases, has examined anthropometric 
measurements in BRCA1/2 mutation carriers and found that neither height nor BMI were related 
to ovarian cancer risk.
18
 Larger, adequately-powered studies are needed to assess whether a 
relationship between either height or BMI and ovarian cancer risk exists for BRCA1/2 mutation 
carriers, and if the direction of association is concordant with that in the general population.  
9 
 
Mendelian randomization (MR) methods use genetic markers associated with a trait as an 
instrumental variable (IV) to assess their potential relationship with a disease outcome.
19-21
 
Compared to traditional epidemiologic approaches, MR can reduce biases such as reverse 
causation and residual confounding, that can interfere with causal interpretations. However, the 
MR approach requires that the genetic variants are associated with the exposure, the variants are 
not or are only weakly associated with confounding factors in the causal pathway, and the 
variants only affect disease risk through the exposure (i.e. absence of pleiotropic effects).
20,21
 To 
the degree that these assumptions are met, the MR approach can strengthen the evidence for a 
causal relationship between exposure and disease.  
Herein, using traditional epidemiologic and MR methods, we conducted analyses of 
height and BMI on ovarian cancer risk in the Consortium of Investigators for the Modifiers of 
BRCA1/2 (CIMBA), with 22,588 participants. We examined heterogeneity of these associations 
with respect to the mutation carried (BRCA1 vs BRCA2), menopausal status, tumor histology, 
and tumor grade.  
 
Methods 
 Characteristics of the CIMBA consortium and information on specific genotyping 
protocols are provided in the Supplementary Methods and were described previously.
22-24
  
 
Selection of Genetic Variants 
 From the latest publications of the Genetic Investigation of Anthropometric Traits, we 
identified SNPs associated with height or BMI at genome-wide significance level (P<5x10
-
10 
 
8
).
11,25
 SNPs with low imputation quality (<0.5) were excluded, leaving 586 SNPs for height and 
93 for BMI. Supplementary Tables 1 and 2 provide additional details on these SNPs.  
 
Statistical Analysis 
 Calculation of the height- and BMI-genetic scores (GS) was described in detail 
previously.
24
 Briefly, we calculated the weighted sums of all of the height- and BMI-associated 
variants under additive models, which do not include interactions between variants. Namely, we 
used the formulas: 𝐻𝑒𝑖𝑔ℎ𝑡 − 𝐺𝑆 = ∑ 𝛽𝑋𝐺𝑖 𝑆𝑁𝑃𝑖
586
𝑖=1  and 𝐵𝑀𝐼 − 𝐺𝑆 = ∑ 𝛽𝑋𝐺𝑖 𝑆𝑁𝑃𝑖
93
𝑖=1 , where βXGi 
is the literature-reported per-allele magnitude of association of the ith-SNP for height and BMI, 
respectively. A scaling factor was calculated by regressing each GS against its respective trait 
among non-case carriers. The corresponding regression coefficients were β0 (intercept=165.455) 
and β1 (slope=5.217) for height and β0 (22.607) and β1 (5.523) for BMI. In the present study, 
BMI-GS was scaled to BMI at date of questionnaire, rather than BMI at age 18, as previous 
GWAS have been based on BMI measurements in middle-aged adults.   
 We subsequently modeled each scaled-GS against ovarian cancer risk using weighted 
Cox models. Our primary outcome of interest was ovarian cancer diagnosis, with individuals 
censored for breast cancer diagnosis, risk-reducing bilateral salpingo-oophorectomy, death, or 
end of follow-up, whichever occurred first. Due to the study design of CIMBA, weights in the 
model were applied for cases and non-cases based on previously observed incidence of ovarian 
cancer in BRCA1/2 carriers.
26,27
 We applied a robust sandwich variance-estimation approach to 
the risk estimates to account for non-independence among multiple carriers per family. 
Additionally, we performed subgroup analyses by BRCA1/2 mutations and menopausal status. 
Menopausal status was defined as a time-varying covariate, coded as premenopausal from birth 
11 
 
until age at natural menopause or bilateral salpingo-oophorectomy. For individuals with missing 
age at menopause, we imputed the age as 50. Imputing missing age at menopause as 46 did not 
materially change the results. The mean and median ages at natural menopause in this population 
were 46 and 48, respectively. All analyses were adjusted for the first eight principal components 
(to account for ethnicity and population stratification), birth cohort, and country of enrollment. 
Additional analyses assessed the associations of height and BMI with ovarian cancer subgroups, 
by histological type (serous vs. non-serous) and by tumor grade (well- or moderately-
differentiated tumors vs. poorly- or un-differentiated).  
 Additionally, phenotype associations with each individual height- and BMI-variant were 
assessed and pooled using inverse variance-weighted meta-analysis. The individual associations 
were obtained by first extracting βXGi for each SNP i, which represents the per-allele magnitude 
of association with height or BMI from previous GWAS. Next, we calculated βYGi and 𝑆𝐸(𝛽𝑌𝐺𝑖) 
using multivariate-adjusted weighted Cox models for each SNP using the CIMBA data, where 
ovarian cancer risk is predicted by genotype G (with G=0,1,2 for the allele corresponding to 
greater height or BMI), principal components, birth cohort, BRCA mutation, and country of 
enrollment. The overall causal association (βYX) is calculated using inverse-variance weighted 
estimate of each variant’s effect: 𝛽𝑌𝑋 =  
∑ 𝛽𝑋𝐺𝑖𝛽𝑌𝐺𝑖𝑆𝐸(𝛽𝑌𝐺𝑖)
−2
𝑖
∑ 𝛽𝑋𝐺𝑖
2
𝑖 𝑆𝐸(𝛽𝑌𝐺𝑖)
−2 . Standard error was estimated as 
𝑆𝐸𝑌𝑋 = √
1
∑ 𝛽𝑋𝐺𝑖
2
𝑖 𝑆𝐸(𝛽𝑌𝐺𝑖)
−2 using the Burgess’s method.
19,28
 Egger’s test was used to assess for 
possible pleiotropic effects of the variants (i.e. whether variants influence the outcome through 
other pathways), to ensure that this assumption held.
29
 
 Finally, in participants with available data on height and BMI, we conducted a formal IV 
analysis using the method of two-stage residual inclusion regression.
30
 In stage one, observed 
height or BMI was regressed against the corresponding GS, principal components, birth cohort, 
12 
 
country, and mutation status. In the second stage, we used a Cox model to fit ovarian cancer risk 
against height or BMI, birth cohort, country, mutation status, and residuals from stage one. 
Variance estimates were obtained through 10,000 boot-straps (see details in Supplementary 
Methods). In these individuals, we also analyzed the association between observed 
measurements of height or BMI and ovarian cancer risk using weighted Cox models, adjusted for 
established ovarian cancer risk factors including birth cohort, menopausal status, age at 
menarche (years) and parity (continuous). The BMI values used were obtained at the date of 
questionnaire, usually close to the date of genetic testing and recalled for BMI at age 18.   
In models with menopausal status as time-varying variable, the test for heterogeneity by 
menopausal status was essentially a test of the proportional hazards assumption. All analyses 
were performed using SAS 9.4 (SAS Institute, Cary, NC) and Stata 14.0 (StataCorp, College 
Station, TX). A two-sided P-value<0.05 was considered statistically significant unless stated 
otherwise.  
 
Results 
Demographic and Clinical Characteristics 
 Characteristics for the 22,588 individuals in the CIMBA consortium, comprising 14,676 
BRCA1 and 7,912 BRCA2 mutation carriers, are shown in Table 1. We documented 2,923 
women with ovarian cancer (BRCA1: 2,319; BRCA2: 604). Compared with non-cases, 
participants who developed ovarian cancer were more often parous women, were younger at first 
live birth, and were from earlier birth cohorts At the date of questionnaire/interview, height 
measurement was available for 7,657 participants and BMI measurement for 7,516 participants. 
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Most tumors for BRCA1/2 mutation carriers were invasive, of serous, poorly/undifferentiated 
grade, and stages 3 or 4 at diagnosis, characteristics which are consistent with prior reports.
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Observed and Predicted Height on Risk of Ovarian Cancer 
 In the survival modelling of ovarian cancer risk, age was used as the underlying time 
scale and the numbers of individuals retained in the analysis were 20535, 14647, 7375, and 2832 
at ages 30, 40, 50, and 60 years, respectively, suggesting that statistical power for the late age is 
limited. After adjustment for birth cohort, country of enrollment, mutation, menopausal status, 
and principal components, a nonsignificant association was found for observed height and 
ovarian cancer risk (HR=1.07 per 10-cm increase, 95%CI: 0.94–1.23, P=0.31) (Table 2). We 
found broadly consistent associations of height in both BRCA1 and BRCA2 mutation carriers, by 
menopausal status, and by tumor histological type and grade.   
 The height-GS was significantly associated with height in all participants, in ovarian 
cancer cases, and in non-case participants (all P<10
-24
) (Supplementary Table 3). Overall, 
approximately 13.4% of the variation in height was explained by the height-GS. Besides height, 
we found weaker associations between the height-GS and body weight, and age-at-menarche. 
 In MR analysis, height-GS had a nonsignificant positive association with ovarian cancer 
risk, HR=1.02 per 10-cm increase in genetically-predicted height, 95%CI: 0.85–1.23, P=0.82 
(Table 3). We found similar associations by subgroups of mutation, menopausal status, and 
tumor grade. 
 Combining the effects of all 586 height-associated variants using inverse-variance 
weighted meta-analysis, we obtained similar findings (HR=1.02, 95%CI: 0.83-1.26, P=0.83) 
(Table 3). Among the SNPs that were combined, there was a low degree of heterogeneity 
14 
 
(I
2
=0%). Examining small-study effects using Egger’s test did not suggest likely pleiotropic 
effects. In the two-stage residual inclusion analysis, the estimated relative risk was larger though 
with wide CIs, which overlapped with those derived using other methods (HR=1.20, 95%CI: 
0.86–1.69, P=0.29). 
 
Observed and Predicted BMI on Risk of Ovarian Cancer 
 After multivariate adjustment, we found a nonsignificant positive association between 
BMI at date of questionnaire and ovarian cancer risk, HR=1.04 per 5-kg/m
2
 increase in BMI, 
95%CI: 0.95–1.14, P=0.42 (Table 4). In a pre-specified analysis, the association between BMI 
and ovarian cancer risk was stronger in premenopausal women (HR=1.25, 95%CI: 1.06–1.48; 
P=0.009) but not in postmenopausal women (HR=0.98, 95%CI: 0.88–1.10), with significant 
interaction (P=0.02). We found that BMI was a significant predictor of non-serous ovarian 
cancer risk (HR=1.25, 95%CI: 1.06–1.49), but not for serous ovarian cancer (HR=0.98, 95%CI: 
0.84–1.15).   
Similar to BMI at date of questionnaire, we detected a significant interaction of BMI in 
young adulthood and menopausal status (P=0.01), with stronger magnitude in premenopausal 
(HR=1.34, 95%CI: 0.97–1.84) compared with postmenopausal women (HR=0.82, 95%CI: 0.65–
1.04).  
BMI-GS was strongly associated with BMI at both date of questionnaire and young 
adulthood (Supplementary Table 4). Overall, the BMI-GS explained 2.6% of the variation in 
BMI at date of questionnaire and 1.7% of the variation in young adulthood BMI. We found 
associations between the BMI-GS and height and age-at-menarche, though the strength of the 
association was weaker than with BMI.  
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 In the entire consortium, the BMI-GS had a nonsignificant positive association with 
ovarian cancer risk with a HR=1.10 per 5-kg/m
2
 of genetically predicted BMI, 95%CI: 0.86–1.42, 
P=0.44 (Table 5). We found heterogeneity by menopausal status (P=0.006). BMI-GS was 
positively associated with ovarian cancer risk in premenopausal women (HR=1.59, 95%CI: 
1.08–2.33) but not in postmenopausal women (HR=0.80, 95%CI: 0.58–1.11). BMI-GS also 
tended to be more associated with non-serous (HR=1.60, 95%CI: 0.83-3.08) than serous tumors 
(HR=0.92, 95%CI: 0.59–1.43).  
 We found similar results when we statistically combined the associations of the 93 BMI-
associated variants, with an overall HR=1.12, 95%CI: 0.86–1.46. Heterogeneity was low 
(I
2
=15.9%), indicating a low likelihood of pleiotropic associations. Using the two-stage residual 
inclusion approach, we found a generally similar association (HR=1.37, 95%CI: 0.84–2.24, 
P=0.21).  
 
Individual SNPs and Ovarian Cancer Risk 
 We found 22 height-associated and 4 BMI-associated SNPs that were nominally 
associated with ovarian cancer risk (P<0.05) (Table 6). None of these SNPs were significantly 
associated with ovarian cancer risk after correcting for multiple testing. We cross-checked these 
identified SNPs with the most up-to-date list of ovarian cancer susceptibility SNPs and did not 
find any overlaps.
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Discussion 
 Using data from a large international consortium of BRCA1/2 mutation carriers, we found 
no statistically significant association between height and ovarian cancer risk. Interestingly, we 
16 
 
observed interactions between BMI (both observed and genetically predicted) and menopausal 
status on ovarian cancer risk, with increasing BMI associated with increased risk in 
premenopausal but not in postmenopausal women.  
 Our finding of a positive association between BMI and overall ovarian cancer risk in 
BRCA mutation carriers is corroborated by several prior studies in the general 
populations.
12,14,15,33
 One MR analysis using 77 BMI-associated SNPs, conducted in the general 
population, found that each 1-standard deviation (SD) increment in genetically-predicted adult 
BMI corresponded to an odds ratio (OR) of 1.35 (95%CI 1.05-1.72).
34
 We found that 5-kg/m
2
 
(about 1 SD) increment in genetically-predicted BMI was associated with a HR=1.10 (95%CI: 
0.86–1.42) in mutation carriers. However, the association of BMI with ovarian cancer risk is 
likely to vary by menopausal status. In the general populations, significant differential 
association of BMI with ovarian cancer risk by menopausal status has been found in some 
studies
15,16,35,36
 but not others.
12,37
 A pooled analysis of 47 epidemiologic studies with 25,157 
ovarian cancer cases showed that the relative risk per 5-kg/m
2
 increase in BMI was 1.12 (95%CI: 
1.07–1.17) in premenopausal women and 1.08 (95%CI: 1.04–1.12) in postmenopausal women.12  
The largest single cohort study, with 3,686 ovarian cancer cases, found the HR per 5-kg/m
2
 
increase in BMI was 1.21 (99%CI: 1.09–1.33) in premenopausal and 1.07 (99%CI: 1.02–1.12) in 
postmenopausal women.
15
 An MR analysis conducted in the general population also observed 
stronger associations for non-high grade serous carcinomas in premenopausal women (OR=1.62, 
95%CI: 0.88–3.01) compared with postmenopausal hormone replacement therapy (HRT) users 
(OR=1.26, 95%CI: 0.57–2.82) and postmenopausal HRT non-users (OR=1.17, 95%CI: 0.61–
2.24), though no formal statistical tests examining heterogeneity were performed.
14
 Similarly, we 
found in BRCA1/2 mutation carriers that 5-kg/m
2
 increment in genetically-predicted BMI was 
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associated with a HR=1.59 (95%CI: 1.08-2.33) for premenopausal ovarian cancer and a 
HR=0.80 (95%CI: 0.58-1.11) for postmenopausal ovarian cancer. Studies which have not 
demonstrated significant variation by menopausal status tended to show that the positive 
association between BMI and ovarian cancer risk was primarily among those who had never 
used HRT.
12
 Taken together, our results and previous literature are suggestive that higher BMI 
may increase ovarian cancer risk in premenopausal women, but not in postmenopausal women. 
Additionally, several studies that had sufficient numbers of patients to evaluate the 
relationship between BMI and ovarian cancer risk by histologic subtype have shown significant 
heterogeneity. Observational studies in the Ovarian Cancer Cohort Consortium found stronger 
associations between BMI and endometrioid (OR=1.17 per 5-kg/m
2
, 95%CI: 1.11–1.23) or 
mucinous ovarian cancer (OR=1.19, 95%CI: 1.06–1.32), but no association with serous ovarian 
cancer (OR=0.98, 95%CI: 0.94–1.02).16 A more recent MR analysis in the same consortium 
using a genetic score comprised of 87 SNPs showed that a genetically predicted BMI had 
stronger association with endometrioid (OR=1.17, 95%CI: 0.87-1.59) or mucinous ovarian 
cancer (OR=1.18, 95%CI: 0.84-1.67) than high grade serous cancer (OR=1.06, 95%CI: 0.89-
1.27), though the 95%CIs for these estimates were largely overlapping.
14
 Consistent with 
findings in the general population, our study in BRCA1/2 mutation carriers showed that BMI was 
positively associated with non-serous ovarian cancer (HR=1.25 per 5-kg/m
2
, 95%CI: 1.06-1.49 
in observed BMI and HR=1.60, 95%CI: 0.83-3.08, per 5-kg/m
2 
in genetically predicted BMI), of 
which endometrioid is a major subtype. Of note, obesity is an established risk factor for 
endometrial cancer.
38
 However, subsequent studies with greater number of cases of different 
ovarian cancer subtypes are needed to assess whether the effect of obesity truly differs by tumor 
subtype.    
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 Our finding of a nonsignificant positive association between height and ovarian cancer 
risk is also consistent with prior epidemiological studies in general populations.
12,37,39
 In the 
general population, 5-cm increment in height was associated with a 7% increase (95%CI: 5-9%) 
in ovarian cancer risk,
12
 and 5-cm increment in genetically predicted height was associated with 
a 6% (95%CI: 1–11%) increase in ovarian cancer risk.39 The associations for observed height did 
not differ significantly between ovarian histological types,
2,12
 while genetically predicted height 
has stronger association with clear cell (OR=1.20, 95%CI: 1.04–1.38) or low grade/borderline 
serous ovarian cancers (OR=1.15, 95%CI: 1.01–1.30), compared to high-grade serous (OR=1.05, 
95%CI: 0.99–1.11).39 We did not find statistically significant heterogeneity by histology in our 
study of mutation carriers, though point estimates varied across histology.  
 Several biological mechanisms potentially explain the associations observed in our study. 
Overweight/obese women are more likely to have anovulatory cycles and fertility issues, 
particularly when caused by polycystic ovarian syndrome (PCOS), and thus have an increased 
risk of ovarian cancer.
40,41
 The association of PCOS and ovarian cancer was mainly confined to 
premenopausal women.
42
 Some studies have suggested that BRCA1/2 mutation carriers may have 
subclinical ovarian insufficiency, which could mediate the relationship between obesity-related 
infertility and increased ovarian cancer risk.
43
 Obesity itself also creates a proinflammatory state 
and adipocyte secreted inflammatory markers have been implicated in ovarian cancer 
development.
44
 Circulating levels of estradiol, androgen, and progesterone have also been 
implicated in the risk of ovarian cancer.
45,46
 One study in BRCA1/2 mutation carriers showed 
higher estradiol levels during each menstrual cycle compared with non-carriers, supporting the 
potential role of sex hormones in ovarian tumorigenesis in this population.
47
 Obese 
premenopausal women tend to have lower circulating levels of progesterone compared with 
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normal weight women.
48
 Higher progesterone levels may reduce ovarian cancer risk, through 
upregulation of p53, leading to tumor cell apoptosis.
46,49-51
 Taken together, these pathways may 
explain the association of higher BMI with premenopausal ovarian cancer risk. Additionally, 
height has been associated with higher levels of circulating insulin-like growth factor-1 (IGF-
1),
52,53
 a pathway that has been implicated in tumor transformation and may exert anti-apoptotic 
and mitogenic effects.
54,55
 Moreover, BRCA1 may directly interact with the IGF-1 pathway to 
mediate cancer risk.
56
  
 Our study has several strengths, including large sample size, genetic scores utilizing most 
identified height- and BMI-variants, several MR methods, and consistent findings between 
observed and genetically-predicted phenotypes. Several limitations of our study should be 
considered. First, even with large sample size, the CIs for most risk estimates were wide, which 
limits inferences about causation. While both the height- and BMI-GS were clearly associated 
with their respective traits, they were only able to explain 13.4% and 2.6% of the variation, 
respectively. This reduced the statistical precision of our risk estimates. During the preparation 
of our manuscript, a new genome-wide meta-analysis
57
 found a substantial number of new 
genetic loci related to height and BMI, increasing the amount of variation that could be explained 
for these two traits to 24.6% and 6.0%, though the variation that could be explained when 
examining these SNPs in a validation cohort was 14.0% and 2.3%. This is comparable to the 
amount of variation that could be explained using the set of genetic variants in our study. 
Including these additional SNPs may be able to improve the precision of our estimates for both 
height and BMI. Moreover, the inclusion of rare variants to strengthen the height and BMI 
genetic instruments should also be considered in future studies.
58
 Our study did not explicitly 
examine whether adding height or BMI (either observed or genetically predicted) to existing 
20 
 
polygenic risk scores for ovarian cancer could further refine risk prediction. Histology was only 
available in a subset of ovarian cancer patients, which limits our capacity to understand subtype-
specific effects of BMI and height. Our study only included women of European ancestry, which 
may preclude generalization to women of other racial/ethnic groups.  
In summary, our study suggests that higher BMI may be causally associated with ovarian 
cancer risk in BRCA1/2 carriers, possibly more so for premenopausal women. BMI could be used 
to identify premenopausal women at elevated risk of ovarian cancer. Our finding of stronger 
association between BMI and non-serous ovarian cancer warrants confirmation in future studies.  
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